Fludarabine
Thymus Neoplasms
National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Thymus Neoplasms cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ribociclib M.D. Anderson Cancer Center | Phase 2 | B |
18f-flt National Cancer Institute (NCI) | Phase 2 | CCC |
Tnhyp217 Car T Cells National Cancer Institute (NCI) | Phase 1 | CC |
Cyclophosphamide National Cancer Institute (NCI) | Phase 1 | CC |
Mithramycin National Cancer Institute (NCI) | Phase 1/2 | D |
Octreotide Pamoate Federico II University | Phase 2 | NR |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →